Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Cash Flow Statements
9 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Cash Flow (OCF) | -1.00 | 36.00 | -65.00 | -61.00 | -103.00 | -49.00 | -225.00 | -333.00 | -394.00 | |
| Operating Cash (Net) | -1.00 | 36.00 | -65.00 | -61.00 | -103.00 | -49.00 | -225.00 | -333.00 | -394.00 | |
| Accounts Receivable | - - | -5.00 | -4.00 | 2.00 | 2.00 | 2.00 | - - | -1.00 | -32.00 | |
| Accounts Payable | - - | 1.00 | - - | - - | 1.00 | 5.00 | - - | -4.00 | 2.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | 10.00 | 59.00 | -16.00 | 3.00 | -20.00 | 57.00 | -22.00 | -53.00 | -52.00 | |
| Other WC | 9.00 | 67.00 | -12.00 | -3.00 | -27.00 | 45.00 | -31.00 | -47.00 | -2.00 | |
| Investing Activities | ||||||||||
| Used Cash (Net) | -2.00 | -6.00 | -10.00 | -260.00 | 25.00 | -214.00 | -550.00 | 160.00 | -31.00 | |
| Capital Expenditure | -2.00 | -6.00 | -10.00 | -6.00 | -6.00 | -3.00 | -12.00 | -58.00 | -13.00 | |
| Purchases of Investments | - - | - - | - - | -254.00 | -297.00 | -473.00 | -1,020.00 | -429.00 | -904.00 | |
| Sale/Maturity of Investment | - - | - - | - - | - - | 329.00 | 262.00 | 485.00 | 647.00 | 887.00 | |
| Property, Plant, Equipment (P&PE) | -2.00 | -6.00 | -10.00 | -6.00 | -6.00 | -3.00 | -12.00 | -58.00 | -13.00 | |
| Acquisitions (Net) | - - | - - | - - | - - | -31.00 | 210.00 | -3.00 | -44.00 | 17.00 | |
| Other Investing Activities | - - | - - | - - | - - | 31.00 | -210.00 | -538.00 | 44.00 | -17.00 | |
| Financing Activities | ||||||||||
| Used Cash (Net) | -70.00 | -167.00 | -142.00 | -40.00 | -76.00 | -371.00 | -736.00 | -582.00 | -130.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
2 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Issued | - - | - - | 141.00 | 28.00 | 72.00 | 358.00 | 736.00 | 565.00 | 119.00 | |
| Repurchased | -2.00 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 72.00 | 167.00 | 1.00 | 11.00 | 4.00 | 13.00 | 736.00 | 17.00 | 10.00 | |
| Cash Balances | ||||||||||
| Begin of Period | 9.00 | 75.00 | 273.00 | 340.00 | 58.00 | 57.00 | 164.00 | 125.00 | 535.00 | |
| End of Period | 75.00 | 273.00 | 340.00 | 58.00 | 57.00 | 164.00 | 125.00 | 535.00 | 240.00 | |
| Change | 65.00 | 197.00 | 67.00 | -281.00 | -1.00 | 107.00 | -39.00 | 409.00 | -295.00 | |
| Non-Cash Balances | ||||||||||
| Depreciation and Amortization | - - | 1.00 | 2.00 | 4.00 | 5.00 | 6.00 | 6.00 | 7.00 | 8.00 | |
| Stock Based Compensation | 1.00 | 6.00 | 15.00 | - - | 15.00 | 19.00 | 47.00 | 91.00 | 134.00 | |
| Other | - - | 6.00 | - - | - - | -3.00 | - - | 2.00 | 95.00 | 6.00 | |
| Highlighted metrics | ||||||||||
| Free Cash Flow (FCF) | -4.00 | 29.00 | -75.00 | -67.00 | -110.00 | -53.00 | -237.00 | -391.00 | -408.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | 25.00 | -58.00 | -18,358.00 | -3,564.00 | 63.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - | - - |